Could a New COVID Pill Crush Vaccine Sales?
Merck (NYSE: MRK) and partner Ridgeback Biotherapeutics soon may bring a game-changing product to market. The companies last week announced positive results from a clinical trial testing their investigational pill to treat coronavirus. If authorized, it would be the first oral treatment for the illness.
This is great news for the companies and for the general public. But shares of vaccine makers like Moderna (NASDAQ: MRNA), BioNTech (NASDAQ: BNTX), and Novavax (NASDAQ: NVAX) tumbled on the news. Investors are worried that an efficacious treatment may mean less need for coronavirus vaccines. But is this true? Could Merck's win equal a revenue loss for the vaccine makers?
Image source: Getty Images.
Source Fool.com
